|
|
|
|
| LEADER |
03781nam a2200757Ia 4500 |
| 001 |
10-1111-bjh-17887 |
| 008 |
220420s2022 CNT 000 0 und d |
| 020 |
|
|
|a 00071048 (ISSN)
|
| 245 |
1 |
0 |
|a Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
|
| 260 |
|
0 |
|b John Wiley and Sons Inc
|c 2022
|
| 300 |
|
|
|a 10
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1111/bjh.17887
|
| 520 |
3 |
|
|a Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related quality of life (HRQoL) in patients with RRMM. Assessment of patient reported-outcome measures from the pivotal, Phase II HORIZON study (OP-106; NCT02963493) in patients with RRMM (n = 64) demonstrated that melphalan flufenamide (melflufen) plus dexamethasone treatment preserved HRQoL. Patients had clinically meaningful improvements, even after eight treatment cycles, in relevant scales such as global health status/QoL, physical functioning, emotional functioning, pain, and fatigue. Patients with triple-class–refractory disease (n = 50) displayed similar improvements. Patient-reported outcome deterioration was delayed for a substantial amount of time in patients who experienced a response to melflufen plus dexamethasone treatment relative to patients who did not experience a response. These findings support the notion that treatment with melflufen plus dexamethasone may sustain or improve HRQoL over time in patients with RRMM, including in patients with triple-class–refractory disease for whom outcomes are generally worse. The clinical benefits observed in patients from the HORIZON trial are encouraging and supportive of translation into real-world practice. © 2021 British Society for Haematology and John Wiley & Sons Ltd
|
| 650 |
0 |
4 |
|a aged
|
| 650 |
0 |
4 |
|a Aged
|
| 650 |
0 |
4 |
|a Aged, 80 and over
|
| 650 |
0 |
4 |
|a antineoplastic agent
|
| 650 |
0 |
4 |
|a Antineoplastic Combined Chemotherapy Protocols
|
| 650 |
0 |
4 |
|a Biomarkers, Tumor
|
| 650 |
0 |
4 |
|a cancer grading
|
| 650 |
0 |
4 |
|a cancer staging
|
| 650 |
0 |
4 |
|a clinical trial
|
| 650 |
0 |
4 |
|a dexamethasone
|
| 650 |
0 |
4 |
|a Dexamethasone
|
| 650 |
0 |
4 |
|a female
|
| 650 |
0 |
4 |
|a Female
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a Humans
|
| 650 |
0 |
4 |
|a male
|
| 650 |
0 |
4 |
|a Male
|
| 650 |
0 |
4 |
|a melphalan
|
| 650 |
0 |
4 |
|a Melphalan
|
| 650 |
0 |
4 |
|a middle aged
|
| 650 |
0 |
4 |
|a Middle Aged
|
| 650 |
0 |
4 |
|a multiple myeloma
|
| 650 |
0 |
4 |
|a Multiple Myeloma
|
| 650 |
0 |
4 |
|a Neoplasm Grading
|
| 650 |
0 |
4 |
|a Neoplasm Staging
|
| 650 |
0 |
4 |
|a Patient Reported Outcome Measures
|
| 650 |
0 |
4 |
|a patient-reported outcome
|
| 650 |
0 |
4 |
|a phase 2 clinical trial
|
| 650 |
0 |
4 |
|a treatment outcome
|
| 650 |
0 |
4 |
|a Treatment Outcome
|
| 650 |
0 |
4 |
|a tumor marker
|
| 650 |
0 |
4 |
|a very elderly
|
| 700 |
1 |
0 |
|a Alegre, A.
|e author
|
| 700 |
1 |
0 |
|a Bakker, N.A.
|e author
|
| 700 |
1 |
0 |
|a Bladé, J.
|e author
|
| 700 |
1 |
0 |
|a Cavo, M.
|e author
|
| 700 |
1 |
0 |
|a Larocca, A.
|e author
|
| 700 |
1 |
0 |
|a Laubach, J.
|e author
|
| 700 |
1 |
0 |
|a Leleu, X.
|e author
|
| 700 |
1 |
0 |
|a Maisel, C.
|e author
|
| 700 |
1 |
0 |
|a Mateos, M.-V.
|e author
|
| 700 |
1 |
0 |
|a Mazumder, A.
|e author
|
| 700 |
1 |
0 |
|a Nadeem, O.
|e author
|
| 700 |
1 |
0 |
|a Oriol, A.
|e author
|
| 700 |
1 |
0 |
|a Orre, M.
|e author
|
| 700 |
1 |
0 |
|a Paner, A.
|e author
|
| 700 |
1 |
0 |
|a Raptis, A.
|e author
|
| 700 |
1 |
0 |
|a Richardson, P.G.
|e author
|
| 700 |
1 |
0 |
|a Rodriguez-Otero, P.
|e author
|
| 700 |
1 |
0 |
|a Sandberg, A.
|e author
|
| 700 |
1 |
0 |
|a Torrång, A.
|e author
|
| 700 |
1 |
0 |
|a Touzeau, C.
|e author
|
| 773 |
|
|
|t British Journal of Haematology
|
